Thomas Hudson has been appointed to the Genome Quebec board of directors. Hudson is president and scientific director of the Ontario Institute for Cancer and a professor in the department of molecular genetics at the University of Toronto.
Additionally, he founded the McGill University and Genome Quebec Innovation Centre, which he managed from 2002 to 2006. He also served as assistant director of the Whitehead/MIT Center for Genome Research and was one of the founders of the International HapMap Consortium, the Public Population Project in Genomics, and the International Cancer Genome Consortium.
Population Genetics has named Alan Schafer as its new CEO. Schafer is an adjunct professor at Imperial College London Business School and was previously the Wellcome Trust's director of science funding. Before that he served as global vice president of technology development at GlaxoSmithKline and co-founded Hexagen, a functional genomics company that was acquired by Incyte.
Jeffrey Crisan and Sheli Rosenberg will not stand for re-election to Nanosphere's board of directors and will instead retire and resign from the board when their current terms are over at the end of May. The company plans to reduce the size of its board from seven to six members after the retirements, and will nominate six nominees for election at its upcoming meeting.